Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Bicycle Therapeutics的主要癌症药物与默沙东的畅销药物联合使用，在尿路上皮癌患者中显示出60%的总体反应率。
On Thursday, Bicycle Therapeutics plc (NASDAQ:BCYC) announced that it presented data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium.
在周四，Bicycle Therapeutics plc（纳斯达克：BCYC）宣布在2024年圣安东尼奥乳腺会议研讨会上展示了zelenectide pevedotin单药治疗在NECTIN4基因扩增的乳腺癌患者中增强的抗肿瘤活性数据。
The company revealed topline combination data for zelenectide pevedotin plus Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab) in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC).
该公司公布了zelenectide pevedotin与默沙东（纽交所：MRK）公司的Keytruda（pembrolizumab）联合治疗在先前未治疗（一线）不适合使用顺铂的转移性尿路上皮癌（mUC）患者中的顶线组合数据。
Topline results from the ongoing Phase 1/2 Duravelo-1 trial evaluating zelenectide pevedotin weekly plus pembrolizumab once every three weeks showed:
正在进行的Duravelo-1一期/二期试验评估每周使用zelenectide pevedotin加每三周一次的pembrolizumab的顶线结果显示：
60% overall response rate (ORR) (12/20) among efficacy-evaluable patients. Of the responses, five were...
在有效性可评估的患者中，总...
登录免费看全文
登录/注册